News Center

Welcome to the Janssen News Center. Here you’ll find our latest press releases, corporate statements, and additional resources.

Press Releases

03/29/2013

U.S. FDA Approves INVOKANA™ (Canagliflozin) to Treat Adults with Type 2 Diabetes

03/14/2013

Doctors Agree Small Lifestyle Changes Can Improve Outcomes of Patients with Type 2 Diabetes, National Survey Finds

02/05/2013

XARELTO^® (rivaroxaban) to be Studied with Factor Xa Inhibitor Antidote

11/02/2012

FDA Approves XARELTO^® (rivaroxaban) to Treat Deep Vein Thrombosis and Pulmonary Embolism, and to Reduce the Risk of Recurrent Events

09/26/2012

FDA Approves Expansion of Dosing Window to Help Avoid Missed Doses in
INVEGA^{^®} SUSTENNA^{^®} Updated Product Label

08/30/2012

Janssen Pharmaceuticals, Inc. announces RISPERDAL^® consumer protection settlement with 36 states and the District of Columbia

08/29/2012

FDA Approves NUCYNTA^{^®} ER (tapentadol) Extended-Release Oral Tablets for the Management of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

05/17/2012

NUCYNTA^® ER (tapentadol) Extended-Release Tablets Show Positive Phase-3 Results in Providing Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)

11/04/2011

FDA Approves XARELTO^{^®}(rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

09/14/2011

New Survey Shows Moderate-to-Severe Acute Pain is Widely Undertreated, Especially Among Older Adults

Corporate Statements

There are no statements at this time.

Additional Resources

Click here for virtual press kits.

© Janssen Pharmaceuticals, Inc. 2013. All Rights Reserved. The use of the information on this site is subject to the terms of our Legal Notice. Please see our Privacy Policy. This site is published by Janssen Pharmaceuticals, Inc., which is solely responsible for its contents. Capitalized product names are trademarks of Janssen Pharmaceuticals, Inc. This information is intended for use by our customers, patients, and healthcare professionals in the United States only. Janssen Pharmaceuticals, Inc., recognizes that the internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The prescribing information included here may not be appropriate for use outside the United States.

This page was last modified on: Mar 29 2013 at 16:43:00 EDT